AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Neumora Therapeutics, Inc. Common Stock
Video analysis: NMRA
All videosNo video analysis for this stock yet. Request one from our team.
News: NMRA
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOAST
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com.
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction.
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with major depressive disorder (MDD).
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) complied with federal securities laws. On June 15, 2026, Neumora announced that “the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary or key secondary endpoints.
